Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2009 1
2012 1
2013 1
2014 3
2015 3
2016 2
2017 3
2018 1
2020 3
2021 5
2022 9
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean quique die (2 results)?
Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study.
Hu X, Cui X, Wang Z, Liu Y, Luo Y, Zhong W, Zhao H, Yao M, Jiang D, Wang M, Chen M, Zheng X, Ding L, Wang Y, Yuan X, Wu P, Hu B, Han X, Shi Y. Hu X, et al. BMC Cancer. 2023 Apr 11;23(1):331. doi: 10.1186/s12885-022-10500-y. BMC Cancer. 2023. PMID: 37041472 Free PMC article. Clinical Trial.
METHODS/DESIGN: In this two-part multicenter phase Ib study, eligible patients with locally advanced or metastatic NSCLC harboring c-MET overexpression or MET exon 14 skipping mutation were enrolled into Part A (tested positive for c-MET overexpression [immunohistochemical staini …
METHODS/DESIGN: In this two-part multicenter phase Ib study, eligible patients with locally advanced or metastatic NSCLC harboring c-MET ove …
Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study.
Xing P, Zhao Q, Zhang L, Wang H, Huang D, Hu P, Sun Y, Shi Y. Xing P, et al. BMC Med. 2022 Nov 23;20(1):453. doi: 10.1186/s12916-022-02646-0. BMC Med. 2022. PMID: 36424628 Free PMC article. Clinical Trial.
METHODS: In this multicenter, single-arm, open-label, first-in-human phase 1 study, conteltinib was taken orally at doses of 50 to 800 mg quaque die (QD) in a dose-escalation phase. If the response was observed in a dose cohort of the dose-escalation phase, dose exp …
METHODS: In this multicenter, single-arm, open-label, first-in-human phase 1 study, conteltinib was taken orally at doses of 50 to 800 mg …
Chloroquine combined with concurrent radiotherapy and temozolomide for newly diagnosed glioblastoma: a phase IB trial.
Compter I, Eekers DBP, Hoeben A, Rouschop KMA, Reymen B, Ackermans L, Beckervordersantforth J, Bauer NJC, Anten MM, Wesseling P, Postma AA, De Ruysscher D, Lambin P. Compter I, et al. Autophagy. 2021 Sep;17(9):2604-2612. doi: 10.1080/15548627.2020.1816343. Epub 2020 Sep 20. Autophagy. 2021. PMID: 32866424 Free PMC article. Clinical Trial.
Favorable toxicity and promising overall survival support further clinical studies.Abbreviations: AE: adverse events; CQ: chloroquine; DLT: dose-limiting toxicities; EGFR: epidermal growth factor receptor; GBM: glioblastoma; HCQ: hydroxychloroquine; IDH1/2: isocitrate dehydrogena …
Favorable toxicity and promising overall survival support further clinical studies.Abbreviations: AE: adverse events; CQ: chloroquine; DLT: …
Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.
Imamura K, Izumi Y, Nagai M, Nishiyama K, Watanabe Y, Hanajima R, Egawa N, Ayaki T, Oki R, Fujita K, Uozumi R, Morinaga A, Hirohashi T, Fujii Y, Yamamoto T, Tatebe H, Tokuda T, Takahashi N, Morita S, Takahashi R, Inoue H. Imamura K, et al. EClinicalMedicine. 2022 Oct 25;53:101707. doi: 10.1016/j.eclinm.2022.101707. eCollection 2022 Nov. EClinicalMedicine. 2022. PMID: 36467452 Free PMC article.
Patients, whose total ALSFRS-R scores decreased by 1-3 points during the 12-week, received escalating doses starting from 100 mg quaque die (QD) up to 400 mg QD based on dose-limiting toxicity (DLT) occurrence, and all participants who received one dose of the study …
Patients, whose total ALSFRS-R scores decreased by 1-3 points during the 12-week, received escalating doses starting from 100 mg quaque …
Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients.
Meng Q, Dong T, Chen X, Tong B, Qian X, Che J, Cheng Y. Meng Q, et al. J Pharm Sci. 2014 Dec;103(12):4038-4047. doi: 10.1002/jps.24174. Epub 2014 Oct 7. J Pharm Sci. 2014. PMID: 25291974 Clinical Trial.
Nineteen treatment-naive HIV patients were treated with s.c.(subcutaneous injection) sifuvirtide [10 or 20 mg q.d.(quaque die)] for 28 days in study 1, and eight treatment-experienced HIV patients were treated with s.c. sifuvirtide (20 mg q.d.) in combination with H …
Nineteen treatment-naive HIV patients were treated with s.c.(subcutaneous injection) sifuvirtide [10 or 20 mg q.d.(quaque die) …
Gut-Selective Design of Orally Administered Izencitinib (TD-1473) Limits Systemic Exposure and Effects of Janus Kinase Inhibition in Nonclinical Species.
Hardwick RN, Brassil P, Badagnani I, Perkins K, Obedencio GP, Kim AS, Conner MW, Bourdet DL, Harstad EB. Hardwick RN, et al. Toxicol Sci. 2022 Mar 28;186(2):323-337. doi: 10.1093/toxsci/kfac002. Toxicol Sci. 2022. PMID: 35134999 Free PMC article.
In rats and dogs, 1000 and 30 mg/kg/day izencitinib, respectively, produced minimal systemic findings (ie, red/white cell changes) and low systemic concentrations (approximately 1 plasma Cave:JAK IC50 ratio) with an 8 nonclinical:clinical systemic area under the curve (AUC) margi …
In rats and dogs, 1000 and 30 mg/kg/day izencitinib, respectively, produced minimal systemic findings (ie, red/white cell changes) and low s …
Clinical data from the real world: Efficacy analysis of ceritinib (450mg) in ALK-rearrangement non-small-cell lung cancer patients with brain metastases in China.
Qiu Z, Xian X, Liu C, Yu M, Lin F, Huang M, Wang K. Qiu Z, et al. J Cancer Res Ther. 2022 Apr;18(2):516-524. doi: 10.4103/jcrt.jcrt_1453_21. J Cancer Res Ther. 2022. PMID: 35645123 Free article.
OBJECTIVES: The real-world intracranial efficacy data of ceritinib at a dose of 450 mg quaque die (QD) are currently unavailable. Therefore, we evaluated the intracranial efficacy of ceritinib (450 mg QD) in anaplastic lymphoma kinase (ALK)-rearrangement NSCLC patie …
OBJECTIVES: The real-world intracranial efficacy data of ceritinib at a dose of 450 mg quaque die (QD) are currently unavailab …
Case Report: A rare case of primary paraganglioma of the gallbladder with a literature review.
Xia Y, Wang S, Wang X, Du J, Zhang L, Xia L. Xia Y, et al. Front Oncol. 2023 Jan 26;12:1031112. doi: 10.3389/fonc.2022.1031112. eCollection 2022. Front Oncol. 2023. PMID: 36776377 Free PMC article.
After surgery, the patient was treated with a new targeted drug, surufatinib {200 mg, q.d. [quaque die (every day)]}, and no recurrence was observed during the regular follow-up. ...
After surgery, the patient was treated with a new targeted drug, surufatinib {200 mg, q.d. [quaque die (every day)]}, and no r …
Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study.
Shi Y, Hu X, Li X, Gong C, Wang K, Li Y, Zhang S, Luo Y, Wang P, Jiang L, Meng X, Dong X, Wang H, Yang R, Mei Q, Liu B, Yang L, Sun Y. Shi Y, et al. J Thorac Oncol. 2024 Jan 29:S1556-0864(24)00035-2. doi: 10.1016/j.jtho.2024.01.015. Online ahead of print. J Thorac Oncol. 2024. PMID: 38295954
METHODS: This first-in-human, phase 1/2 study (Chinese Clinical Trial Registry identifier: ChiCTR1900025619; ClinicalTrials.gov identifier: NCT05257512) had two parts. Phase 1 included a dose-escalation phase (25-800 mg quaque die [QD]) and a dose-expansion phase (5 …
METHODS: This first-in-human, phase 1/2 study (Chinese Clinical Trial Registry identifier: ChiCTR1900025619; ClinicalTrials.gov identifier: …
Preparation and Characterization of a Novel Swellable and Floating Gastroretentive Drug Delivery System (sfGRDDS) for Enhanced Oral Bioavailability of Nilotinib.
Lin HL, Chen LC, Cheng WT, Cheng WJ, Ho HO, Sheu MT. Lin HL, et al. Pharmaceutics. 2020 Feb 6;12(2):137. doi: 10.3390/pharmaceutics12020137. Pharmaceutics. 2020. PMID: 32041184 Free PMC article.
Regarding compliance and minimization of side effects of nilotinib therapy, there is a medical need to have a gastroretentive drug delivery system (GRDDS) to enhance the oral bioavailability that is able to administer an optimal dose in a quaque die (QD) or daily ma …
Regarding compliance and minimization of side effects of nilotinib therapy, there is a medical need to have a gastroretentive drug delivery …
34 results